International audienceD-serine, as a co-agonist of N-methyl-D-aspartate subtype of glutamate receptors (NMDAR), is a key regulator of their activation and hence involves in functional brain plasticity and memory process. The homeostasis of these receptors is affected by soluble oligomers of the beta-amyloid peptide (Aß) in Alzheimer´s disease (AD). In the course of AD, early functional dysregulations of NMDAR are well known, even though contribution of D-serine remains so far to be determined. In 3-4 month-old transgenic mice model of amyloïdogenesis (5xFAD) showing marked increase in Aß rates and apparent unaffected D-serine levels, extracellular electrophysiological recordings reveal impaired NMDAR-dependent long-term potentiation at CA1/...
Detecting and treating Alzheimer's disease, before cognitive deficits occur, has become the health c...
A heterogeneous mixture of amyloid beta (Aβ) variants exists in Alzheimer’s disease (AD) brains. So ...
Alzheimer's disease (AD) is a neurodegenerative disease, characterised by the presence of amyloid p...
In recent years, failures in clinical settings to treat Alzheimer's disease (AD), create an urge for...
International audienceB fEPSP/PFV ra>o 0 0,2 0,4 0,6 0,8 1 1,2 1,4 1,6 WT 5xFAD 5xFAD/SR-/-+ D-s e r...
International audienceD-serine, as a co-agonist of N-methyl-D-aspartate subtype of glutamate recepto...
Memory loss is among the first symptoms reported by patients suffering from Alzheimer’s disease (AD)...
Les échecs cliniques de ces dernières années concernant le traitement de la maladie d’Alzheimer (MA)...
La perte de mémoire est un des premiers symptômes caractéristiques de la maladie d’Alzheimer (MA). D...
Serotonin, 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter with a wide range of biologica...
International audienceAlteration of brain aerobic glycolysis is often observed early in the course o...
Subtle losses of memory or changes in behavior are the first outward signs of Alzheimer’s disease (A...
The recent failure of major Alzheimer’s disease (AD) clinical trials would indicate that, at the mom...
Detecting and treating Alzheimer's disease, before cognitive deficits occur, has become the health c...
A heterogeneous mixture of amyloid beta (Aβ) variants exists in Alzheimer’s disease (AD) brains. So ...
Alzheimer's disease (AD) is a neurodegenerative disease, characterised by the presence of amyloid p...
In recent years, failures in clinical settings to treat Alzheimer's disease (AD), create an urge for...
International audienceB fEPSP/PFV ra>o 0 0,2 0,4 0,6 0,8 1 1,2 1,4 1,6 WT 5xFAD 5xFAD/SR-/-+ D-s e r...
International audienceD-serine, as a co-agonist of N-methyl-D-aspartate subtype of glutamate recepto...
Memory loss is among the first symptoms reported by patients suffering from Alzheimer’s disease (AD)...
Les échecs cliniques de ces dernières années concernant le traitement de la maladie d’Alzheimer (MA)...
La perte de mémoire est un des premiers symptômes caractéristiques de la maladie d’Alzheimer (MA). D...
Serotonin, 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter with a wide range of biologica...
International audienceAlteration of brain aerobic glycolysis is often observed early in the course o...
Subtle losses of memory or changes in behavior are the first outward signs of Alzheimer’s disease (A...
The recent failure of major Alzheimer’s disease (AD) clinical trials would indicate that, at the mom...
Detecting and treating Alzheimer's disease, before cognitive deficits occur, has become the health c...
A heterogeneous mixture of amyloid beta (Aβ) variants exists in Alzheimer’s disease (AD) brains. So ...
Alzheimer's disease (AD) is a neurodegenerative disease, characterised by the presence of amyloid p...